Work

P1.12B.06 Deulorlatinib (TGRX-326)in Patients with ALK Fusion-Positive NSCLC: Update from the Phase 1 Trial

Year: 2024

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2024.09.365

Authors: L. Zhang, H. Zhao, S. Zhao, H. Zhou, Y. Ma, N. Yang, Z. Wang, W. Jin, X. Li, Y. Liu, R. Meng, J. Zhou, Y. Cheng, Y. Wang, Z. Yu

Institutions: Sun Yat-sen University Cancer Center, Central South University, Shandong Tumor Hospital, Jiangxi Provincial Cancer Hospital, First Affiliated Hospital of Zhengzhou University, First Hospital of China Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, First Affiliated Hospital Zhejiang University, Jilin Province Tumor Hospital, West China Hospital of Sichuan University, Affiliated Hospital of Qingdao University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403410101

FWCI:

Cites:

Cited by:

Related to: 10